| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
6-Bnz-cAMP sodium salt selectively targets the cyclic AMP-binding domains of protein kinase A (PKA) regulatory subunits (RI and RII). Upon binding, it induces a conformational change that leads to dissociation of the catalytic subunits, which then phosphorylate Ser/Thr residues on downstream protein targets. It has negligible affinity for Epac1 and Epac2, the other major cAMP-binding proteins. This exquisite selectivity makes it the standard pharmacological tool for specifically activating PKA in cells without engaging Epac-mediated pathways. It does not target adenosine receptors.
|
|---|---|
| ln Vitro |
In vitro, 6-Bnz-cAMP sodium salt selectively activates PKA in cell-free assays with an EC50 in the low micromolar range (typically 1-10 uM). In cell-free kinase assays using purified PKA holoenzyme (50 nM), 6-Bnz-cAMP (10 uM) stimulates catalytic activity by >10-fold, comparable to cAMP. In contrast, it shows no activation of Epac proteins in nucleotide exchange assays (using Epac-specific FRET-based sensors). At concentrations up to 500 uM, no activation of Epac is observed, confirming the exquisite selectivity. The compound also inhibits proliferation of vascular smooth muscle cells (VSMC) in combination with 8-CPT-2Me-cAMP (an Epac activator), demonstrating synergistic effects on cell growth.
|
| ln Vivo |
6-Bnz-cAMP sodium salt is not typically used in vivo as a therapeutic agent, but it has been used in animal studies as a research tool to activate PKA and investigate physiological processes. For example, in a rat model of myocardial infarction, intracoronary administration of 6-Bnz-cAMP (10 uM) improved left ventricular function by increasing PKA-mediated phosphorylation of phospholamban, thereby enhancing cardiac contractility. In mice, intraperitoneal injection of 50 mg/kg 6-Bnz-cAMP increased CREB phosphorylation in the hippocampus and was used to study memory consolidation. The compound's rapid cell permeability makes it useful for ex vivo tissue studies.
|
| Enzyme Assay |
The compound is not used in purified enzyme binding assays for receptor occupancy measurement. Instead, standard PKA activity assays are used. For the cAMP-dependent PKA activation assay, a non-radioactive method: Prepare a reaction mixture containing 50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 0.1 mM ATP, 50 uM kemptide substrate (LRRASLG), and 0.1 ug PKA holoenzyme. Add 0.1-100 uM of 6-Bnz-cAMP sodium salt. Incubate at 30degC for 10 minutes. The phosphorylated peptide is detected by a PKA kinase activity kit using a specific antibody against phosphorylated kemptide by ELISA or by ADP-Glo luminescence. EC50 for activation is determined. A control using cAMP (1-100 uM) serves as a positive control for full activation. Epac activation can be assessed in a separate assay using a FRET-based EPAC sensor.
|
| Cell Assay |
For cell-based assays: HEK293T, HeLa, or primary cardiomyocytes are seeded in 6-well plates (1×10⁶ cells/well) and grown to 70-80% confluence. Cells are serum-starved overnight. Then, cells are treated with 6-Bnz-cAMP sodium salt (1-500 uM) or vehicle (control) for 15-60 minutes. PKA activation is assessed by Western blotting for phosphorylated CREB (p-CREB Ser133). For functional studies, a reporter plasmid containing CRE-luciferase is transfected into cells 24 hours before treatment. After 6 hours of treatment, cells are lysed, and luciferase activity is measured. Alternatively, cells are incubated with a FRET-based PKA activity reporter (e.g., AKAR3). Real-time FRET imaging captures PKA activation kinetics. Co-treatment with the PKA inhibitor H-89 (10 uM) confirms specificity.
|
| Animal Protocol |
For in vivo studies in rodents: Male C57BL/6 mice (8-10 weeks old) are used. 6-Bnz-cAMP sodium salt is dissolved in sterile PBS or saline at a concentration of 10 mg/mL. Mice receive intraperitoneal injection of 25-100 mg/kg. Blood and tissues are collected 30-120 minutes after injection. For cardiac studies, rats are anesthetized, and 6-Bnz-cAMP is infused into the left anterior descending coronary artery via a catheter at 10-100 uM for 10 minutes. For memory studies, mice receive intrahippocampal injection (0.5-2 ug/side). After treatment, animals undergo behavioral testing (e.g., novel object recognition, fear conditioning). At endpoint, brains are collected, and CREB phosphorylation (p-CREB Ser133) is measured by immunohistochemistry or Western blot to confirm PKA activation.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data are available for 6-Bnz-cAMP sodium salt. The compound is a cyclic nucleotide analog that is resistant to degradation by phosphodiesterases (PDEs) to some extent but may still be hydrolyzed in vivo. The benzoyl modification at the N6 position enhances cell permeability and PKA selectivity while conferring some resistance to PDEs. Following IP injection in mice, peak tissue levels are reached within 30-60 minutes. The compound is likely excreted via the kidneys or metabolized by tissue PDEs and phosphatases. No formal ADME studies have been published. The compound is soluble in water (≥50 mg/mL) and DMSO (≥100 mg/mL). Stock solutions are stable at -20degC for several months.
|
| Toxicity/Toxicokinetics |
Based on the safety data sheet, 6-Bnz-cAMP sodium salt may cause skin and eye irritation. It is harmful if swallowed (oral LD50 500-2000 mg/kg predicted). Inhalation of dust may cause respiratory tract irritation. No carcinogenicity, mutagenicity, or reproductive toxicity data are available. The compound is stable under recommended storage conditions (powder at -20degC, desiccated, protected from light). Standard laboratory precautions should be used: fume hood, gloves, safety goggles, lab coat. In case of skin contact, wash with soap and water; for eye contact, flush with water for 15 minutes. The compound is not classified as a hazardous material for transportation under DOT regulations.
|
| References | |
| Additional Infomation |
6-Bnz-cAMP sodium salt is not an approved drug and has no clinical trial or regulatory approval history. It is a research chemical used as a pharmacological tool for signal transduction studies. The compound is often used in combination with Epac-specific activators (e.g., 8-CPT-2Me-cAMP) to dissect the relative contributions of PKA and Epac pathways in cellular processes such as gene expression, insulin secretion, cardiac contractility, synaptic plasticity, and immune cell activation. It is commercially available for research use only. Understanding PKA selectivity has also informed the development of therapeutic cAMP analogs for potential clinical applications in heart failure, diabetes, and neurological disorders. However, the compound itself is not being developed as a drug.
|
| Molecular Formula |
C17H15N5NAO7P
|
|---|---|
| Molecular Weight |
455.29
|
| Exact Mass |
455.06
|
| CAS # |
1135306-29-4
|
| PubChem CID |
23672707
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
31
|
| Complexity |
716
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)NC(=O)C5=CC=CC=C5)O)OP(=O)(O1)[O-].[Na+]
|
| InChi Key |
SPYGSKQRPXISIB-FKVBDRBCSA-M
|
| InChi Code |
InChI=1S/C17H16N5O7P.Na/c23-12-13-10(6-27-30(25,26)29-13)28-17(12)22-8-20-11-14(18-7-19-15(11)22)21-16(24)9-4-2-1-3-5-9;/h1-5,7-8,10,12-13,17,23H,6H2,(H,25,26)(H,18,19,21,24);/q;+1/p-1/t10-,12-,13-,17-;/m1./s1
|
| Chemical Name |
sodium;N-[9-[(4aR,6R,7R,7aS)-7-hydroxy-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]purin-6-yl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1964 mL | 10.9820 mL | 21.9640 mL | |
| 5 mM | 0.4393 mL | 2.1964 mL | 4.3928 mL | |
| 10 mM | 0.2196 mL | 1.0982 mL | 2.1964 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
